Pfizer grants ChemRar Group exclusive license to DPP-IVi T2D candidate

Pfizer has granted SatRx, a company belonging to Russian pharmaceutical investment and R&D group ChemRar Hi-Tech Centre, exclusive development and marketing rights to for its DPP(1)-IVi…